Navigation Links
Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
Date:2/11/2009

BOCA RATON, Fla., Feb. 11 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG, Dreieich, Germany, announced that it has acquired a plasma collection facility located at 2860 Cerrillos Road, Santa Fe, New Mexico from Talecris Plasma Resources, Inc. With this acquisition, BPC now operates 11 plasma centers in various locations throughout the United States. Last year, the company announced it had aggressive plans for further expansion during the next two years. BPC will continue to explore opportunities to expand its plasma collection operations to address the global demand for this very important source material. Financial terms of the purchase were not disclosed.

"We are extremely pleased to add the Santa Fe facility to our network of plasma centers in the U.S.," remarked Dr. Rainer Pabst, Chief Executive Officer of BPC. "We are looking forward to continuing to build upon our existing foundation to reach our goals of continued growth and expanded range of top-quality plasma products."

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 560 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 1,850 people worldwide.

To learn more about Biotest Pharmaceuticals and how we help make a difference in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and immunological diagnostics which are used, for example, in blood transfusions and transplants. Biotest has around 1,950 employees worldwide and its shares are listed in the Stock Exchange's SDAX on the Frankfurt Stock Exchange.


'/>"/>
SOURCE Biotest Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
2. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: